Establishes guidelines for the expansion of high-quality public prekindergarten education programs for children ages three (3) and four (4) to increase children’s school readiness.
Provides that the department of elementary and secondary education, in consultation with a workgroup composed of various stakeholders, develop a funding formula for school districts sending students to career and technical programs outside their district.
Requires the EOHHS to amend the state Medicaid plan and secure sufficient state general revenue to increase Medicaid payment rates to an amount equal to one hundred thirty percent (130%) of Medicare rates for outpatient clinical pediatric services.
Exempts from the sales tax eligible school supplies, costing less than $30.00, purchased within one week prior to the commencement of the academic year.
Imposes a non-owner occupied property tax on residential properties assessed in excess of eight hundred thousand dollars ($800,000) at variable rates dependent on values assessed by local tax assessors.
Increases the net taxable estate exemption to $3,600,000 on January 1, 2026 and increases the exemption by $1,000,000 on January 1, 2027, and every year thereafter.
Establishes a revolving fund to assist first-time home buyers and veterans to purchase a home in Rhode Island by issuing grants of up to forty thousand dollars ($40,000).
Requires each healthcare entity/network plan to compile/report to health insurance commissioner a summary of how the healthcare entity/network plan requires its contracted providers to submit claims for in-network outpatient behavioral health services.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Limits prior authorization requirements for rehabilitative and habilitative services. Also prohibits prior authorization for the first twelve (12) visits of a new episode of care and for ninety (90) days following a chronic pain diagnosis.
Establishes a process whereby large drug manufacturers, may be penalized for prescription drug price increases where there is no, or inadequate, new evidence to support the price increase.